Belinostat: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Belinostat. Educational only — not medical advice.
Labeled uses
Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response [see Clinical Studies ( 14 )]. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Source: FDA labeling via NIH DailyMed (set 2e8ef36b…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.